Daily FNArena News

This week’s Tweets by Your Editor on Twitter.

REVA Medical has seen the timeline for starting clinical trials of its bioresorbable stent slip but Bell Potter says any associated share price weakness would be a buying opportunity.

Barclays Capital has analysed seasonal trends for September.

PFP Wealth Management’s Tim Price reviews the book ‘Extreme Money – Masters of the Universe and the Cult of Risk’, which suggests the world needs reduce debt and shrink the financial part of the economy.

A profit result better than guidance and expectations of further growth lead Microequities to retain a Strong Buy rating on IT junior BigAir.

The Chartist suggests a “significant low” has likely been seen for National Australia Bank shares.

ATW’s Jerry Simmons reports the rally in US equities might find the going tougher as strong technical resistance is looming.

Daily update on share prices and consensus price targets.

The ECB has been the most hawkish of the major central banks so far this year, but maybe not for much longer, reports Forex.com’s Kathleen Brooks.

A well received full year profit result and a solid growth outlook suggest value in Tox Free Solutions at current levels.